EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 遠大醫藥集團有限公司 | | 股份代號 | 00512 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至二零二五年十二月三十一日止年度之末期股息 | | | 公告日期 | 2026年3月26日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.169 HKD | | 股東批准日期 | 2026年6月5日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.169 HKD | | 匯率 | 1 H ...

Financial Performance - For the year ending December 31, 2025, the company's revenue was approximately HKD 12,283,270,000, representing a year-on-year growth of about 5.5%, and a growth of approximately 14.8% when excluding the impact of centralized procurement price reductions[2]. - The adjusted operating profit attributable to the company's owners was approximately HKD 1,494,260,000, a decrease from HKD 1,760,650,000 in the previous year, primarily due to the impact of centralized procurement price reductions[5]. - The company reported a net profit of HKD 1,244,303,000 for the year, down 49.6% from HKD 2,466,059,000 in 2024[178]. - Total comprehensive income for the year ended December 31, 2025, was HKD 1,450,458,000, a decrease of 34% from HKD 2,202,873,000 in 2024[179]. - Basic and diluted earnings per share for 2025 were HKD 35.44, down from HKD 70.49 in 2024, representing a decline of 50.3%[179]. Revenue Breakdown - Revenue from nuclear medicine oncology and cardiovascular precision intervention products was approximately HKD 1,282,080,000, a significant increase of about 57.1% compared to HKD 816,210,000 in the previous year[119]. - The pharmaceutical technology segment generated revenue of approximately HKD 7,294,290,000, remaining nearly flat compared to HKD 7,317,840,000 in the previous year[120]. - The biotechnology segment recorded revenue of approximately HKD 3,706,910,000, reflecting a year-on-year increase of about 5.6% from HKD 3,510,840,000[121]. Research and Development - The company invested approximately HKD 1.46 billion in research and development, including capitalized R&D expenses and prepayments for new projects[5]. - The group has a total of 131 ongoing research projects, including 39 innovative projects at various stages from preclinical to new drug application[131]. - The group has established multiple R&D platforms globally, including a pharmaceutical technology R&D center in Wuhan, China, and an mRNA technology platform in Nanjing, focusing on anti-tumor and anti-infection mRNA drugs[134]. Product Development and Innovation - The innovative product STC3141 for treating sepsis successfully reached its primary clinical endpoint in Phase II trials, with ongoing communication with international regulatory authorities[6]. - The innovative product GPN01530 for diagnosing solid tumors received FDA approval to initiate Phase I/II clinical studies, enhancing its international development capabilities[6]. - The innovative nuclear medicine pipeline has nearly 30 products, with about 50% being self-developed, and four products in Phase III clinical trials, including TLX591-CDx, which is expected to enter the new drug application phase in 2026[9]. Market Expansion and Strategy - The company is committed to a "Go Global" strategy, enhancing its international presence and commercial network, particularly for self-developed innovative drugs like GPN01530 and STC3141[14]. - The company emphasized that innovation-driven strategies and global expansion are essential for navigating industry challenges and achieving long-term growth[7]. - The group has accelerated its globalization efforts, with over 330 employees overseas and 8 clinical approvals obtained in the US, Australia, Belgium, Poland, and the UK for various indications[140]. Operational Efficiency - The company has improved its operational scale and business structure, enhancing profitability and integrating acquisitions to solidify its growth[15]. - Distribution costs and administrative expenses were approximately HKD 3,806,890,000 and HKD 1,389,090,000, respectively, with distribution costs increasing by about HKD 550,000,000 due to intensified marketing efforts for new products[123]. - The company’s financial expenses decreased to HKD 162,338,000 from HKD 180,242,000, reflecting better cost management[178]. Shareholder Returns - The board proposed a final dividend of HKD 0.169 per share, totaling approximately HKD 591,810,000, reflecting the company's commitment to shareholder returns[5]. - The proposed final dividend per share for 2025 is HKD 0.169, a decrease from HKD 0.26 in 2024, resulting in total dividends of HKD 591,806,000 compared to HKD 910,471,000 in the previous year[199]. Acquisitions and Investments - The group completed the acquisition of a 30.64% stake in Nanjing Kainet Medical Technology Co., Ltd., increasing its ownership to 59.81%, enhancing its capabilities in high-end medical device R&D and production[23]. - The group signed an agreement to acquire 80% of Qinghai Yixin for RMB 392 million, gaining exclusive rights to several traditional Chinese medicine products, strengthening its market position in chronic disease treatment[143]. - The group plans to acquire all shares of Hebei Yuanda Jiufu and Baoding Jiahe for RMB 316 million, aiming to strengthen its biotechnology supply chain and enhance product offerings[145]. Financial Position - As of December 31, 2025, the group's current assets amounted to HKD 8,307,530,000, an increase from HKD 8,025,520,000 as of December 31, 2024[149]. - The group's current liabilities as of December 31, 2025, were HKD 7,316,710,000, compared to HKD 6,573,220,000 as of December 31, 2024, resulting in a current ratio of approximately 1.14[149]. - The group's cash and bank balances as of December 31, 2025, were HKD 1,142,370,000, down from HKD 1,340,980,000 as of December 31, 2024[149].

自願性公告 本集團中藥 1 類創新藥 GPN01020 在中國獲批開展 II 期臨床研究 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 (股份代號：00512) 本集團作為中國主要的五官科藥物研發、生產及銷售綜合企業之一，在售產品管線數量 位居行業前列，治療領域覆蓋包括眼科、耳鼻喉科、口腔科等多科室疾病，覆蓋了化學 製劑、中藥製劑及健康產品，包含處方藥、OTC、器械、消費品等幾大類別，建立了專 業化營銷團隊，形成了覆蓋全國的營銷網絡。中成藥是本集團五官科板塊的重要佈局的 方向之一，本集團立足中醫藥在慢病治療領域的核心優勢，持續深耕中成藥賽道，在鞏 固並完善五官科產品矩陣的基礎上，通過戰略佈局脈血康系列產品、丹珍頭痛膠囊、 ...

Core Viewpoint - The approval of GPN01768, a global innovative ophthalmic drug for treating Demodex blepharitis, marks a significant advancement in addressing a previously underserved medical need in China and globally [2][3]. Group 1: Product Approval and Market Potential - GPN01768 is the only drug specifically designed for treating Demodex blepharitis, which has been approved in China after its launch in the United States in 2023 [3]. - The condition affects over 400 million patients worldwide, with projections indicating it will exceed 500 million by 2029. In China, the patient population consistently exceeds 50 million, highlighting a substantial clinical demand and market opportunity [3]. - The global ophthalmic drug market is expected to reach approximately $70.3 billion by 2033, with the Chinese market projected to surpass $10 billion by 2032 and reach $11.9 billion by 2033, indicating significant growth potential [3]. Group 2: Financial Performance and Company Strategy - After its approval in the U.S., GPN01768 generated $180 million in revenue in 2024, with an anticipated revenue of approximately $450 million in 2025, reflecting a year-on-year growth of over 150% [4]. - The company has been actively expanding its presence in the ophthalmic drug market through a combination of partnerships and in-house development, with a pipeline that includes treatments for dry eye syndrome, postoperative inflammation and pain, pterygium, and myopia [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，本集團引進的用於治療蠕形蟎瞼緣炎的全球創新眼科藥物 GPN01768 [TP-03，(洛替拉納滴眼液) 0.25%]近日正式獲得中華人民共和國國家藥品監督管理局 (「藥監局」)頒發的藥品註冊證書，且在藥品審評過程中未收到補充資料通知，實現「零 發補」獲批上市。本集團於二零二四年三月與 Tarsus Pharmaceuticals, Inc. (「Tarsus Pharmaceuticals」，TP-03 的開發者)達成產品引進戰略合作協議，獲得在大中華區（中 國大陸、中國香港特別行政區、中國澳門特別行政區、中國台灣地區）的獨家開發、生 產及商業化權益。此次該產品獲批上市是本集團在五官科板塊眼科創新藥方向上的又一 項重要進展。 蠕形蟎是導致蠕形蟎瞼緣炎的根本原因，GPN01768 是一 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕大註冊成立之有限公司 ) (股份代號: 00512) 盈利警告 遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)根據香港聯合交 易所有限公司證券上市規則第 13.09(2)條及香港法例第 571 章證券及期貨條例第 XIVA 部項下內幕消息條文而發出本公告。 本公司之董事會(「董事會」)謹此知會本公司股東(「股東」)及潛在投資者，根據本公司 現時所得資料及本公司管理層對本集團截至二零二五年十二月三十一日止年度的未經 審核管理賬目所作出的初步審閱，預期截至二零二五年十二月三十一日止年度的本公司 擁有人應佔期內溢利在 12.0 億港元至 12.5 億港元之間，二零二四年同期經審核的本公 司擁有人應佔期內溢利約為 24.7 億港元。預期截至二零二五年十二月三十一日止年度 的本公司擁有人應佔經調 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* 融資授信協議 遠大醫藥（香港）有限公司（本公司全資子公司）作為借款人（「借款人」），本公司及 本公司若干附屬公司作為擔保人，若干銀行作為貸款人（「貸款人」）已就 8 億港元的 定期融資（「融資」）簽訂融資授信協議（「融資授信協議」）。 該融資期限為自該融資展 期生效日期起計 36 個月止。 控制人的具體履行義務 根據融資授信協議的條款，若（其中包括）（1）胡凱軍先生及其配偶周彤女士（統稱「控 制人」）一致行动，合計不再實益擁有（直接或間接）至少 45% 該公司發行的股本; (2) 任何個人或一致行動團體成為公司的實益擁有人，且其投票股本大於或等于控制人， 則貸款人可以取消其在融資授信協議下的承諾，並宣報所有未償還貸款，應計利息以及 根據貸款協議應付的所有其他應計或未償還金額立即到期。 -1- 只要產生上市規則第 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 董事會召開日期 遠大醫藥集團有限公司(「本公司」)之董事會(「董事會」)謹此宣佈，本公司將於 二零二六年三月二十六日(星期四)舉行董事會會議，藉以(其中包括)考慮及批准本公司 及其附屬公司截至二零二五年十二月三十一日止之全年業績以及派發末期股息等事 宜。 承董事會命 遠大醫藥集團有限公司 主席 唐緯坤博士 香港，二零二六年三月十七日 於本公告日期，董事會由四名執行董事唐緯坤博士、周超先生、林芷伊女士以及楊光先 生，及四名獨立非執行董事蘇彩雲女士、邢麗娜博士、裴更博士及胡野碧先生組成 。 * 僅供識別 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕大註冊成立之有限公司 ) (股份代號: 00512) ...

致：香港交易及結算所有限公司 公司名稱: 遠大醫藥集團有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00512 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證 ...

Investment Rating - The report does not explicitly state an investment rating for the dry eye disease treatment industry Core Insights - The dry eye disease market in China is experiencing significant growth, with the number of patients increasing from 300 million in 2020 to 360 million in 2024, representing a compound annual growth rate (CAGR) of approximately 5% [7] - The treatment rate for dry eye disease remains low at 10%-12%, indicating substantial market potential [3] - The market is evolving from traditional artificial tears to innovative therapies, including preservative-free formulations and new drug delivery systems, driven by advancements in formulation technology [3] - Local pharmaceutical companies are making breakthroughs in anti-inflammatory mechanisms and targeted therapies, leading to a new competitive landscape focused on innovative drugs and precision treatment [3] Market Background - The dry eye disease market has evolved through three stages: the nascent stage (1995-2005), the initiation stage (2006-2015), and the rapid development stage (2016-present) [5][6] - The current market is characterized by a shift from foreign dominance to a competitive landscape involving both domestic and foreign companies [12] Market Status - The market size is projected to reach 139 billion yuan in 2024, with expectations to grow to 193 billion yuan by 2030, reflecting a CAGR of about 9% [7] - The supply chain includes high-activity raw materials and a diverse range of products, with foreign companies currently holding a significant market share in artificial tears [8] - Demand for treatments is increasing, particularly among moderate to severe dry eye patients who require combination therapies [9] Market Competition - The competitive landscape is marked by a clear tiered structure, with leading companies like Santen Pharmaceutical and domestic firms like Xingqi Eye Medicine dominating the first tier [12] - The report identifies ten key brands in the market, highlighting their strengths and market positions [13] - Domestic companies are increasingly closing the gap with foreign firms through innovation and strategic partnerships [12] Development Trends - The market is expected to maintain a growth rate of around 9% from 2025 to 2030, driven by advancements in diagnostic technologies and innovative therapies [27] - Drug innovation is diversifying, with traditional drugs being upgraded and new treatment modalities emerging [28] - Local companies are expanding globally, with firms like Heng Rui Medicine and Xingqi Eye Medicine leading the charge in international markets [29]